{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "marketState": "REGULAR", "regularMarketPrice": 3.26, "exchange": "MUN", "shortName": "KINNATE BIOPHARMA -,0001", "longName": "Kinnate Biopharma Inc.", "messageBoardId": "finmb_557510592", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChangePercent": 0.0, "firstTradeDateMilliseconds": 1606978800000, "priceHint": 4, "regularMarketChange": 0.0, "regularMarketTime": 1683871320, "regularMarketDayHigh": 3.26, "regularMarketDayRange": "3.26 - 3.26", "regularMarketDayLow": 3.26, "regularMarketVolume": 600, "regularMarketPreviousClose": 3.26, "bid": 3.58, "ask": 3.64, "fullExchangeName": "Munich", "financialCurrency": "USD", "regularMarketOpen": 3.26, "averageDailyVolume3Month": 0, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 1.0799999, "fiftyTwoWeekLowChangePercent": 0.4954128, "fiftyTwoWeekRange": "2.18 - 15.3", "fiftyTwoWeekHighChange": -12.04, "fiftyTwoWeekHighChangePercent": -0.7869281, "fiftyTwoWeekLow": 2.18, "fiftyTwoWeekHigh": 15.3, "earningsTimestamp": 1683835503, "earningsTimestampStart": 1691611500, "earningsTimestampEnd": 1692043500, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -3.05, "sharesOutstanding": 46569600, "bookValue": 5.04, "fiftyDayAverage": 4.3544, "fiftyDayAverageChange": -1.0944002, "fiftyDayAverageChangePercent": -0.251332, "twoHundredDayAverage": 8.02135, "twoHundredDayAverageChange": -4.7613497, "twoHundredDayAverageChangePercent": -0.5935846, "marketCap": 151816896, "priceToBook": 0.6468254, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "symbol": "6KB.MU"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "103 Montgomery Street", "address2": "Suite 150 The Presidio of San Francisco", "city": "San Francisco", "state": "CA", "zip": "94129", "country": "United States", "phone": "858 299 4699", "website": "https://www.kinnate.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.", "fullTimeEmployees": 84, "companyOfficers": [{"maxAge": 1, "name": "Mr. Nima  Farzan M.B.A.", "age": 46, "title": "Pres, CEO & Director", "yearBorn": 1976, "fiscalYear": 2022, "totalPay": {"raw": 891954, "fmt": "891.95k", "longFmt": "891,954"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 3230306, "fmt": "3.23M", "longFmt": "3,230,306"}}, {"maxAge": 1, "name": "Ms. Neha  Krishnamohan", "age": 35, "title": "CFO, Principal Accounting Officer and Exec. VP of Corp. Devel.", "yearBorn": 1987, "fiscalYear": 2022, "totalPay": {"raw": 548950, "fmt": "548.95k", "longFmt": "548,950"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Mark A. Meltz", "age": 48, "title": "COO, Gen. Counsel, Treasurer & Sec.", "yearBorn": 1974, "fiscalYear": 2022, "totalPay": {"raw": 671864, "fmt": "671.86k", "longFmt": "671,864"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 938185, "fmt": "938.18k", "longFmt": "938,185"}}, {"maxAge": 1, "name": "Ms. Priyanka  Shah", "title": "VP of Investor Relations & Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Barbara  Warren", "title": "VP of People & Culture", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Richard Thomas Williams MBBS, Ph.D.", "age": 53, "title": "Chief Medical Officer", "yearBorn": 1969, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Robert  Kania Ph.D.", "title": "Sr. VP of Drug Discovery", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jason  Hampson M.D.", "title": "VP and Head of Regulatory Affairs & Quality", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Christian  Dimaano", "title": "VP & Head of Medical Affairs", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 7, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}